Oragenics (NYSE:OGEN) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Oragenics (NYSE:OGEN) in a research report report published on Friday. The brokerage issued a sell rating on the stock.

Oragenics Price Performance

OGEN stock opened at $0.35 on Friday. The firm has a 50 day simple moving average of $0.79 and a two-hundred day simple moving average of $1.18. The stock has a market cap of $1.98 million, a PE ratio of -0.05 and a beta of 0.45. Oragenics has a one year low of $0.35 and a one year high of $7.74.

Oragenics (NYSE:OGEN) last announced its earnings results on Friday, August 9th. The company reported ($0.51) earnings per share (EPS) for the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Oragenics stock. Virtu Financial LLC bought a new stake in shares of Oragenics, Inc. (NYSE:OGEN) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 22,675 shares of the company’s stock, valued at approximately $33,000. Virtu Financial LLC owned about 0.51% of Oragenics as of its most recent filing with the Securities and Exchange Commission. 18.71% of the stock is owned by hedge funds and other institutional investors.

Oragenics Company Profile

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.